INTRACRINE DYNAMICS OF CYP17A1 ACTIVITIES IN HUMAN CASTRATION RESISTANT PROSTATE CANCER

被引：0
|
作者：
Kosaka, Takeo
Miyajima, Akira
Maeda, Takahiro
Nagata, Hirohiko
Yasumizu, Yota
Kikuchi, Eiji
Oya, Mototsugu
机构：
来源：
JOURNAL OF UROLOGY | 2013年 / 189卷 / 04期
关键词：
D O I：
10.1016/j.juro.2013.02.1900
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
506
引用
收藏
页码：E207 / E208
页数：2
相关论文
共 50 条
  • [41] Anticancer activity of the selective CYP17A1 inhibitor, VT-464, in preclinical models of castrate-resistant prostate cancer
    Toren, Paul
    Pham, Steven
    Kim, Soojin
    Adomat, Hans
    Zoubeidi, Amina
    Moore, William R.
    Gleave, Martin Edwin
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [42] Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer
    St-Laurent, Marie-Pier
    Black, Peter C.
    EUROPEAN UROLOGY, 2024, 86 (02) : 185 - 186
  • [43] Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer
    Huang, Audris
    Jayaraman, Lata
    Fura, Aberra
    Vite, Gregory D.
    Trainor, George L.
    Gottardis, Marco M.
    Spires, Thomas E.
    Spires, Vanessa M.
    Rizzo, Cheryl A.
    Obermeier, Mary T.
    Elzinga, Paul A.
    Todderud, Gordon
    Fan, Yi
    Newitt, John A.
    Beyer, Sophie M.
    Zhu, Yongxin
    Warrack, Bethanne M.
    Goodenough, Angela K.
    Tebben, Andrew J.
    Doweyko, Arthur M.
    Gold, David L.
    Balog, Aaron
    ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (01): : 40 - 45
  • [44] ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer
    Peltola, Katriina J.
    Bono, Petri
    Jones, Robert Hugh
    Vjaters, Egils
    Nykanen, Pirjo
    Vuorela, Annamari
    Oksala, Riikka
    Pohjanjousi, Pasi
    Mustonen, Mika V. J.
    Fizazi, Karim
    Massard, Christophe
    EUROPEAN UROLOGY FOCUS, 2020, 6 (01): : 63 - 70
  • [45] ODM-204 a novel dual inhibitor of CYP17A1 and androgen receptor: Early results from phase I dose escalation in men with castration-resistant prostate cancer
    Fizazi, Karim
    Jones, Robert Hugh
    Massard, Christophe
    Vjaters, Egils
    Peltola, Katriina Johanna
    Nykänen, Pirjo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [46] CYP17A1 and CYP21A2, enzymology and their human deficiency states
    Auchus, Richard J.
    DRUG METABOLISM REVIEWS, 2011, 43 : 9 - 10
  • [47] EN3356, a novel CYP17A inhibitor for the treatment of castration resistant prostate cancer.
    Laping, Nicholas J.
    Sivanandhan, Dhanalakshmi
    Kethiri, Raghava Reddy
    Dewang, Purushottam M.
    Vijayendra, Ajith
    Zainuddin, Mohd
    Mullangi, Ramesh
    Rao, Niranjan
    Venkatesan, Aranapakam M.
    Reddy, Sanjeeva
    Gupta, Sandeep
    Smith, Roger A.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [48] CYP17A1 and abiraterone: Implications for breast cancer endocrine therapy
    Capper, Cameron P.
    Johnson, Michael D.
    Larios, Jose M.
    Rae, James M.
    CANCER RESEARCH, 2014, 74 (19)
  • [49] ANTI-CANCER ACTIVITY OF THE SELECTIVE CYP17A1 INHIBITOR, VT-464, IN PRE-CLINICAL MODELS OF CASTRATE RESISTANT PROSTATE CANCER
    Toren, Paul
    Pham, Steven
    Kim, Soojin
    Adomat, Hans
    Zoubeidi, Amina
    Moore, William
    Gleave, Martin
    JOURNAL OF UROLOGY, 2014, 191 (04): : E808 - E808
  • [50] CYP11A1 inhibition as a therapeutic approach for the treatment of castration resistant prostate cancer
    Oksala, R.
    Rasanen, K.
    Karimaa, M.
    Riikonen, R.
    Ramela, M.
    Vehmaan-Kreula, P.
    Simola, O.
    Rummakko, P.
    Wohlfahrt, G.
    Mustonen, M.
    ANNALS OF ONCOLOGY, 2018, 29
12345